SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar (CSIQ) is trending due to widespread community allegations of market manipulation and a recent convertible notes offering, which many shareholders perceive as detrimental, fueling frustration over its valuation despite strategic moves in US manufacturing and IRA tax credit potential.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending amid highly polarized community discussions, with supporters championing its "culture first" mission on Solana and the broader cannabis legalization movement, while critics widely label it as a pump-and-dump meme coin without intrinsic value.

Moo Deng

MOODENG CRYPTO is generating significant buzz and buying interest, with the community actively discussing its potential for explosive upward movement amid a broader bullish sentiment for meme coins. Many are accumulating, citing its relatively low market cap and high trading volume as key indicators for a substantial rally.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy is trending as the crypto community discusses its innovative approach to real estate tokenization, driven by an upcoming first on-chain property sale and a recently unveiled 2025 roadmap detailing AI integration. While many view its low market cap as ripe for growth in the Real World Assets (RWA) sector, others remain cautious, citing past price volatility and skepticism.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending amid ongoing strategic review processes and multiple acquisition bids, notably a rejected "undervalued" offer from its CEO and interest from Hapag-Lloyd. The community is actively discussing the company's significant undervaluation and the potential for a bidding war, alongside concerns over Israeli government approval for the strategic asset.

Southern Copper Corp. engages in the development, production, and exploration of copper, molybdenum, zinc, and silver. It operates through the following segments: Peruvian Operations, Mexican Open-Pit Operations, and Mexican Underground Mining Operations. The Peruvian Operations segment focuses on the Toquepala and Cuajone mine complexes and the smelting and refining plants, industrial railroad, and port facilities that service both mines. The Mexican Open-Pit Operations segment comprises the La Caridad and Buenavista mine complexes, the smelting, and refining plants and support facilities, which service both mines. The Mexican Underground Mining Operations segment is involved in the operation of five underground mines, a coal mine, and several industrial processing facilities. The company was founded on December 12, 1952 and is headquartered in Phoenix, AZ.

Southern Copper Corporation

Southern Copper is trending as copper prices reach record highs, driven by soaring demand from AI, data centers, EVs, and grid upgrades, coupled with significant global supply disruptions. The community is actively discussing the company's strong earnings, ambitious growth plans, and the potential impact of US copper tariffs amidst a projected long-term structural deficit for the metal.

Bridgford Foods Corp. engages in the manufacture, market, and distribution of frozen and snack food products. It operates through the Frozen Food Products and Snack Food Products segments. The Frozen Food Products segment manufactures and distributes food products, including biscuits, bread dough items, roll dough items, and sandwiches. The Snack Food Products segment distributes both products manufactured by the company and third parties. The company was founded by Hugh H. Bridgford in February 1932 and is headquartered in Dallas, TX.

Bridgford Foods Corp.

Bridgford Foods Corporation

Bridgford Foods (BRID) is trending as the community speculates on a significant boost to its gross margins from President Trump's initiatives to lower beef prices through increased imports. Investors are also noting the company's aggressive push into private-label offerings with major retailers, viewing it as a deeply undervalued defensive play within the strengthening food sector.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is trending due to strong positive Phase 3 data for its cancer drug Ziihera in gastroesophageal cancer and recent FDA accelerated approval for biliary tract cancer. This success is driving significant share price gains and analyst upgrades, with the community actively discussing Ziihera's potential as a new oncology standard of care and the company's overall valuation.

Hudbay Minerals, Inc. operates as a mining company. The firm engages in the production of copper concentrate, molybdenum concentrate and zinc metal. It focuses on the discovery, production and marketing of base and precious metals. The company was founded on January 16, 1996 and is headquartered in Toronto, Canada.

Hudbay Minerals Inc.

Hudbay Minerals is gaining significant attention as copper prices reach record highs, driven by growing global demand from EVs and infrastructure, with its Copper World project serving as a key long-term catalyst. The community is buzzing with optimism about HBM's growth potential and strategic initiatives, despite recent stock volatility and a capital raise for further development.

Ero Copper Corp. engages in the exploration, development, and mining of mineral properties in Brazil. It also produces and sells copper, gold, silver products. The company was founded on May 16, 2016 and is headquartered in Vancouver, Canada.

Ero Copper Corp

Ero Copper Corp. is trending due to record copper production and the successful ramp-up of its Brazilian projects, sparking community debate about its valuation and potential for sustained growth. The discussion is amplified by surging copper demand from the energy transition and AI infrastructure, positioning it as a possible next major commodity rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare (NASDAQ:IXHL) Announces Quarterly Earnings Results

Incannex Healthcare (NASDAQ:IXHL - Get Free Report) issued its earnings results on Friday. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02...

Incannex Healthcare (IXHL) Expected to Announce Quarterly Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) will be releasing its Q2 2026 earnings before the market opens on Friday, February 13. (View Earnings Report at...

Short Interest in Incannex Healthcare Inc. (NASDAQ:IXHL) Decreases By 30.9%

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totaling 15,236,764 shares...

Incannex Healthcare (NASDAQ:IXHL) Trading Up 2.1% - Still a Buy?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.1% - Time to Buy...

Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Here's What Happened

Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Should You Sell...

Penny Stocks To Keep An Eye On - December 3rd

iRobot, Richtech Robotics, Bitfarms, Virax Biolabs Group, Nauticus Robotics, Incannex Healthcare, and Fusion Fuel Green are the seven Penny stocks to watch today, according to MarketBeat's stock...

<ul class="summary-bullets"><li>FDA Fast Track status followed strong Phase 2 efficacy and safety results for IHL-42X.</li><li>The designation provides benefits including a rolling review and closer FDA engagement.</li><li>Stocktwits users highlighted the scale of OSA unmet need and long-term optimism.</li></ul>Incannex Healthcare shares rose nearly 15% on Wednesday after the company said the U.S. Food and Drug Administration (FDA) granted Fast Track designation to IHL-42X, its oral fixed-dose combination candidate for obstructive sleep apnea.<h2 class="st-heading-2">FDA Fast Track Status</h2>Incannex said the designation was supported by results from three completed clinical trials, including its Phase 2 RePOSA study, which showed statistically significant reductions in Apnea-Hypopnea Index with individual reductions of up to 83%, along with favorable patient-reported outcomes and an “excellent safety profile.”The company said the Fast Track status allows more frequent interactions with the FDA, eligibility for rolling review of a future New Drug Application, and potential access to Accelerated Approval and Priority Review if criteria are met.Incannex said it expects detailed written feedback from the FDA on its Phase 2 data package and development strategy and will provide updates once it has reviewed the agency’s guidance.<h2 class="st-heading-2">Generalized Anxiety Disorder Data Adds Momentum</h2>In August, the company reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">positive mid-stage trial results</a> for PSX-001 in generalized anxiety disorder. The study showed statistically significant improvements across all key endpoints, including a strong reduction on the Hamilton Anxiety Rating Scale among 73 participants.<h2 class="st-heading-2">Stocktwits Traders Cheer Fast Track Status</h2>On Stocktwits, retail sentiment for Incannex was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:971/140;" src="https://news.stocktwits-cdn.com/ixhl_ss_png_fd98f44272.webp" alt="ixhl ss.png" width="971" height="140"><figcaption>IXHL sentiment and message volume as of December 3| Source: Stocktwits</figcaption></figure>One user said, “this is incredible news. Fast tracked serves unmet medical needs, meaning this is the only pill in existence for a disease that affect nearly a billion people.”<stembedurl>https://stocktwits.com/user0987134/message/638044052</stembedurl>Another bullish user called the stock a “long hold” and expects further positive developments.<stembedurl>https://stocktwits.com/Rusty26/message/638043151</stembedurl><a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare’s stock</a> has declined 79% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Incannex Healthcare Stock Soars 15% After FDA Fast Tracks Obstructive Sleep Apnea Drug

Incannex’s Fast Track designation for IHL-42X follows strong Phase 2 data and grants the program expanded FDA access and review advantages.

Equity

What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock

Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Incannex Healthcare (NASDAQ:IXHL) Trading Up 1.1% - Still a Buy?

Incannex Healthcare (NASDAQ:IXHL) Shares Up 1.1% - Time to Buy...

Incannex Healthcare Inc. (IXHL) has experienced a 234% increase in retail chatter on Stocktwits over the past seven days, while message volumes have risen 193% over the past 30 days on the platform. Shares of the company drew investor attention on Wednesday morning as it declined nearly 10% at the opening bell.Incannex is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:574/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_9_16_43_AM_png_8958508111.webp" alt="IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="66"><figcaption>IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">announced </a>positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The company stated that the trial results confirm statistically significant and clinically meaningful improvements across all key endpoints assessed, including the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group.Of patients receiving treatment, 27% achieved complete disease remission, which is five times higher than the placebo rate, the company said. Additionally, the firm is exploring strategic partnerships to accelerate development and broaden global access to PSX-001.The company’s other two clinical-stage product candidates, IHL-42X and IHL-675A, are in different stages of development. While IHL-42X has completed a mid-stage clinical trial in obstructive sleep apnoea, IHL-675A is currently in a mid-stage clinical development program for the treatment of inflammatory conditions such as Arthritis.Incannex also <a href="https://stocktwits.com/news-articles/markets/equity/incannex-stock-soars-after-board-authorizes-20-million-share-repurchase-program/chsZIp3RdK2">authorized</a> a $20 million share repurchase program in August. CEO Joel Latham had stated that the program reflects the company’s confidence in the strength of its pipelines and the opportunities ahead. “We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs,” he said.A Stocktwits user, meanwhile, expressed hopes for a partnership or buyout announcement on the company’s next earnings announcement.<stembedurl>https://stocktwits.com/IKEGAI/message/629801176</stembedurl>Shares of the company slumped 71% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR